Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus

To determine prognostic factors for mortality in a cohort of 667 patients with systemic lupus erythematosus (SLE) including those variables associated with the presence of antiphospholipid antibodies (aPL) as well as antiphospholipid syndrome (APS) itself. Analysis of the cohort under a nested case...

Full description

Saved in:
Bibliographic Details
Published inJournal of rheumatology Vol. 21; no. 6; p. 1067
Main Authors Drenkard, C, Villa, A R, Alarcón-Segovia, D, Pérez-Vázquez, M E
Format Journal Article
LanguageEnglish
Published Canada 01.06.1994
Subjects
Anemia, Hemolytic - complications
Antiphospholipid Syndrome - complications
Arterial Occlusive Diseases - complications
Cohort Studies
Humans
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - mortality
Multivariate Analysis
Prognosis
Proportional Hazards Models
Risk Factors
Survival Analysis
Thrombocytopenia - complications
Online AccessGet more information

Cover

More Information
Summary:To determine prognostic factors for mortality in a cohort of 667 patients with systemic lupus erythematosus (SLE) including those variables associated with the presence of antiphospholipid antibodies (aPL) as well as antiphospholipid syndrome (APS) itself. Analysis of the cohort under a nested case control design by means of Cox proportional hazards regression with and without stepwise method. During the 2039 person-years of followup, there were 49 deaths (cases). Thrombocytopenia, arterial occlusions, and hemolytic anemia were the aPL related manifestations that were associated with decreased survival in univariate analyses. The first 2 were also selected among risk factors for mortality in stepwise Cox multivariate analysis. The syndrome itself was also associated with increased mortality rates, independently of other variables. APS is among the variables that confer decreased survival on patients with SLE. This decreased survival is due to some (e.g., thrombocytopenia or arterial occlusions), but not all, of the manifestations of APS.
ISSN:0315-162X